<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01374776</url>
  </required_header>
  <id_info>
    <org_study_id>Version number 2 fro</org_study_id>
    <nct_id>NCT01374776</nct_id>
  </id_info>
  <brief_title>Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women</brief_title>
  <official_title>Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance In Non Anemic Premenopausal Women With Low Ferritin Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Effect of intravenous iron substitution (iron carboxymaltose (Ferinject®), total dose 15 mg/&#xD;
      kg (maximal dose: 1000mg) in 250 ml 0.9 % NaCl; intravenous infusion in 20 min)in non-anemic&#xD;
      premenopausal women with iron deficiency on&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      - Mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of&#xD;
      the lower leg muscle)&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Maximal oxygen uptake during a graded cycling exercise test and time to exhaustion at&#xD;
           submaximal power during a constant-load cycling exercise test&#xD;
&#xD;
        -  Plantarflexor muscle fatiguability as assessed by isokinetic dynamometry&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mitochondrial capacity (Phosphocreatine Recovery rate assessed by 31P-MR-spectroscopy of the lower leg muscle)</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Non Anemic Patients With Iron Deficiency (Low Ferritin Value)</condition>
  <arm_group>
    <arm_group_label>intravenous iron carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous iron carboxymaltose infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous iron carboxymaltose</intervention_name>
    <description>The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.</description>
    <arm_group_label>intravenous iron carboxymaltose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: INCLUSION CRITERIA&#xD;
&#xD;
          -  Healthy female subjects, Age &gt; 18 years, premenopausal, regularly menstruating&#xD;
&#xD;
          -  BMI 18-25 kg/m2.&#xD;
&#xD;
          -  Serum ferritin level &lt; 15ug/ml&#xD;
&#xD;
          -  Recreationally active with = 1.5 h/w structured activity&#xD;
&#xD;
          -  Adequate contraception during the study period&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion criteria: EXCLUSION CRITERIA&#xD;
&#xD;
          -  Anemia with Hb level &lt; 120 g/l&#xD;
&#xD;
          -  Known hypersensitivity to iron carboxymaltose, iron sucrose or iron sulfate&#xD;
&#xD;
          -  Intake of iron preparations (also multivitamins containing iron) during the last 8&#xD;
             weeks before the start of the trial protocol&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Any cardiovascular or pulmonary disease&#xD;
&#xD;
          -  Any orthopaedic or rheumatologic disease which affects exercise performance&#xD;
&#xD;
          -  Presence of muscle disease&#xD;
&#xD;
          -  Acute or chronic infection/inflammation or malignancy&#xD;
&#xD;
          -  Known mental disorders (e.g. depression)&#xD;
&#xD;
          -  Intake of concurrent medication, except oral contraceptives&#xD;
&#xD;
          -  CRP &gt; 10 mg/l&#xD;
&#xD;
          -  TSH out of normal range&#xD;
&#xD;
          -  Elevated CK (&gt; 167 U/l)&#xD;
&#xD;
          -  Any concurrent medical condition(s) that, in the view of the investigator, would&#xD;
             prevent compliance or participation or jeopardize the health of the patients.&#xD;
&#xD;
          -  Participation in any other therapeutic trial within the previous month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre-Alexandre Krayenbuehl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Clinic and Policlinic of Internal Medicine</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2011</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

